Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 84-90

  Sakata, Akiko ^a   Mogi, Masaki ^a   Iwanami, Jun ^a   Tsukuda, Kana ^a   Min, Li Juan ^a   Jing, Fei ^a   Ohshima, Kousei ^a   Ito, Masaharu ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cognitive impairment; gender specific medicine; Morris water maze test; passive avoidance test; sex difference; spironolactone; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL TEST; FEMALE; GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MAZE TEST; MENTAL TEST; MORRIS WATER MAZE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARIECTOMY; SEX DIFFERENCE; SHUTTLE AVOIDANCE TEST; SPATIAL MEMORY; WILD TYPE;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; ELECTROLYTES; ESTRADIOL; FEMALE; HORMONES; MALE; MEMORY; MICE; ORGAN SIZE; OVARIECTOMY; SPIRONOLACTONE; SYSTOLE;

EID: 84859951538     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311412810     Document Type: Article

References (23)

1. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160: 174-180. (Pubitemid 30054336)
2. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E and Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658-663. (Pubitemid 39100821)
3. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr and Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005; 330: 1360.
4. Sakata A, Mogi M, Iwanami J, et al. Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice. Life Sci 2010; 86: 638-645.
5. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686-692.
6. Mogi M, Li JM, Iwanami J, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148. (Pubitemid 44297536)
7. Krege JH, Hodgin JB, Hagaman JR and Smithies O. A non-invasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995; 25: 1111-1115.
8. Sakata A, Mogi M, Iwanami J, et al. Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice. Life Sci 2010; 86: 638-345.
9. Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 2008; 149: 3764-3777.
10. Engelmann M, Landgraf R, Lorscher P, et al. Downregulation of brain mineralocorticoid and glucocorticoid receptor by antisense oligodeoxynucleotide treatment fails to alter spatial navigation in rats. Eur J Pharmacol 1998; 361: 17-26.11.
11. Oitzl MS and de Kloet ER. Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 1992; 106: 62-71.
12. Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM and Mattson MP. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci 2008; 11: 309-317. (Pubitemid 351311802)
13. Herrero AI, Sandi C and Venero C. Individual differences in anxiety trait are related to spatial learning abilities and hippocampal expression of mineralocorticoid receptors. Neurobiol Learn Mem 2006; 86: 150-159. (Pubitemid 44287574)
14. Smythe JW, Murphy D, Timothy C and Costall B. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacol Biochem Behav 1997; 56: 507-513. (Pubitemid 27145833)
15. Ackermann TF, Boini KM, Volkl H, et al. SGK1-sensitive renal tubular glucose reabsorption in diabetes. Am J Physiol Renal Physiol 2009; 296: F859-866.
16. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.
17. Yagi S, Akaike M, Aihara K, et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 2011; 34: 74-78.
18. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD and Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008; 51: 762-768.
19. Rigsby CS, Burch AE, Ogbi S, Pollock DM and Dorrance AM. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1754-R1763. (Pubitemid 47535795)
20. Burgess LH and Handa RJ. Estrogen-induced alterations in the regulation of mineralocorticoid and glucocorticoid receptor messenger RNA expression in the female rat anterior pituitary gland and brain. Mol Cell Neurosci 1993; 4: 191-198. (Pubitemid 23108720)
21. Arias-Loza PA, Hu K, Dienesch C, et al. Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 2007; 50: 432-438. (Pubitemid 47205796)
22. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57: 442-451.
23. Hammond R and Gibbs RB. GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance. Brain Res 2011; 1379: 53-60.